CERo Therapeutics Holdings, Inc. (CERO) stock
CEROOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CEROW
$0.01+0.00 (0.00%)
Close on Oct 19, 2026Market cap $253.05KP/E –Yield 172833.33%
CERo Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
CERo Therapeutics's R&D Expenses for the twelve months ending Dec 31, 2023 was $5.29M. For fiscal 2023 it was $5.29M.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $5.29M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.74M | -40.3% |
| Q1 FY2026 | Mar 31, 2026 | $2.34M | +31.8% |
| Q3 FY2025 | Sep 30, 2025 | $2.39M | -12.1% |
| Q2 FY2025 | Jun 30, 2025 | $2.75M | +170.5% |
| Q1 FY2025 | Mar 31, 2025 | $2.91M | +127.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.77M | +48.7% |
| Q2 FY2024 | Jun 30, 2024 | $2.71M | +50.8% |
| Q4 FY2023 | Dec 31, 2023 | $1.02M | – |
| Q3 FY2023 | Sep 30, 2023 | $1.28M | – |
| Q2 FY2023 | Jun 30, 2023 | $1.19M | – |
| Q1 FY2023 | Mar 31, 2023 | $1.80M | – |
See a number that looks wrong?